2018
DOI: 10.1111/apt.14861
|View full text |Cite
|
Sign up to set email alerts
|

Letter: screening for adrenal suppression in paediatric inflammatory bowel disease

Abstract: Linked ContentThis article is linked to Philpott et al papers. To view these articles visit https://doi.org/10.1111/apt.14573 and https://doi.org/10.1111/apt.14954.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
4
0

Year Published

2018
2018
2020
2020

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(4 citation statements)
references
References 7 publications
0
4
0
Order By: Relevance
“…37 The conflicting results in the literature are in part due to the infrequent utilization of the gold standard ACTH stimulation test 38 and many have advocated for more consistent testing and monitoring. 39 Our study has many limitations; most evident are referral and selection bias. We have a sizeable number of patients with EoO being managed at our institution, and by comparison only a small proportion of them also underwent DEXA scans.…”
Section: Discussionmentioning
confidence: 90%
See 1 more Smart Citation
“…37 The conflicting results in the literature are in part due to the infrequent utilization of the gold standard ACTH stimulation test 38 and many have advocated for more consistent testing and monitoring. 39 Our study has many limitations; most evident are referral and selection bias. We have a sizeable number of patients with EoO being managed at our institution, and by comparison only a small proportion of them also underwent DEXA scans.…”
Section: Discussionmentioning
confidence: 90%
“…Only a minority of patients on TS for EoO had associated adrenal insufficiency in a recent meta‐analysis 37 . The conflicting results in the literature are in part due to the infrequent utilization of the gold standard ACTH stimulation test 38 and many have advocated for more consistent testing and monitoring 39 …”
Section: Discussionmentioning
confidence: 99%
“…reporting that proton pump inhibitors (PPIs) might increase the risk of hepatocellular carcinoma (HCC) with an adjusted odds ratio (OR) of 2.86 (95% CI, 2.69-3.04). A doseresponse effect was also reported in this study 1. In view of the widespread use of PPIs for acid-related disorders and inconsistent results reported in previous studies, we conducted a meta-analysis to further investigate the association between long-term PPI use and the risk of HCC.Two investigators independently reviewed published studies in PUBMED and EMBASE from inception to July 2018 using a search strategy that included the terms for "PPIs" and "HCC."…”
mentioning
confidence: 78%
“…We read with great interest the recent observational study by Shao-met all inclusion criteria. [1][2][3][4][5] The pooled OR from these five studies was 1.58 (95% CI 0.91-2.76; P = 0.105; I 2 = 97.7%; P herterogeneity < 0.001) ( Figure 1A). We then performed a sensitivity analysis after excluding two studies that included patients with chronic hepatitis B or C infection.…”
Section: Editorsmentioning
confidence: 99%